Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference.Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signal...

Full description

Bibliographic Details
Main Authors: Si Su, Liuqing Wu, Guibao Zhou, Lingling Peng, Huanzhe Zhao, Xiao Wang, Kuan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Pharmacology
Subjects:
denosumab
zoledronic acid
adverse events
off-label use
pharmacovigilance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1225919/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1225919/full

Similar Items